公开(公告)号：US12109225B2

公开(公告)日：2024-10-08

申请号：US17293103

申请日：2019-11-11

申请人： GLYCOMIRA THERAPEUTICS, INC.

发明人： Won Yong Lee ,  Thomas P. Kennedy ,  Glenn D. Prestwich

IPC分类号： A61K38/00 ,  A61K31/737 ,  A61K41/00 ,  A61N5/10

CPC分类号： A61K31/737 ,  A61K41/0038 ,  A61N5/1001 ,  A61N5/1077 ,  A61N5/1084 ,  A61N2005/1024 ,  A61N2005/1087 ,  A61N2005/109 ,  A61N2005/1091 ,  A61N2005/1098

摘要： Described herein are methods for reducing or maintaining the size of a tumor in a subject, where the method involves exposing the tumor to ionizing radiation and administering to the subject a modified hyaluronan or a pharmaceutically acceptable salt or ester. The use of the modified hyaluronan enhances or potentiates the effect of ionizing radiation used in cancer treatment. Additionally, the methods described herein prevent or reduces tumor regrowth in the subject after exposing the tumor to ionizing radiation and administration of the modified hyaluronan to the subject.

公开(公告)号：US20240199656A1

公开(公告)日：2024-06-20

申请号：US18277623

申请日：2022-02-21

申请人： The University of Tokyo

发明人： Yasuteru URANO ,  Mako KAMIYA ,  Junya TSUNETOMI

IPC分类号： C07F5/02 ,  A61K51/04 ,  A61N5/10

CPC分类号： C07F5/027 ,  A61K51/04 ,  A61N5/1077 ,  A61N2005/1098

摘要： [Problem] To provide a novel compound promising as a probe for a boron neutron capture therapy (BNCT).
[Solution] A compound represented by general formula (I) below or a salt thereof.

公开(公告)号：US11987614B2

公开(公告)日：2024-05-21

申请号：US17397577

申请日：2021-08-09

申请人： Omniox, Inc.

发明人： Gregory Kapp ,  Laura Serwer ,  Natacha Le Moan ,  Stephen P. L. Cary

IPC分类号： C07H21/00 ,  A61K38/16 ,  A61K38/41 ,  A61K45/06 ,  A61N5/10 ,  C07K14/795 ,  G01N33/53 ,  G01N33/574 ,  A61K38/00

CPC分类号： C07K14/795 ,  A61K38/164 ,  A61K38/41 ,  A61K45/06 ,  A61N5/10 ,  G01N33/53 ,  G01N33/57407 ,  A61K38/00 ,  A61N2005/1098 ,  C07K2319/21 ,  G01N2800/52 ,  Y02A50/30

摘要： The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.

公开(公告)号：US20240100361A1

公开(公告)日：2024-03-28

申请号：US18455506

申请日：2023-08-24

申请人： Varian Medical Systems, Inc.

发明人： Renate PARRY ,  Eric ABEL ,  Swati GIRDHANI ,  Stanley MANSFIELD ,  Patrick KUPELIAN ,  Deepak KHUNTIA

IPC分类号： A61N5/10 ,  A61K9/00 ,  A61K9/14 ,  A61K9/51 ,  A61K31/352 ,  A61K31/366 ,  A61K31/404 ,  A61K31/436 ,  A61K31/4439 ,  A61K33/242 ,  A61K33/244 ,  A61K45/06 ,  A61P35/00 ,  G16H20/40

CPC分类号： A61N5/1031 ,  A61K9/0009 ,  A61K9/141 ,  A61K9/51 ,  A61K31/352 ,  A61K31/366 ,  A61K31/404 ,  A61K31/436 ,  A61K31/4439 ,  A61K33/242 ,  A61K33/244 ,  A61K45/06 ,  A61N5/1042 ,  A61N5/1084 ,  A61P35/00 ,  G16H20/40 ,  A61N5/1043 ,  A61N5/1045 ,  A61N2005/1087 ,  A61N2005/1088 ,  A61N2005/1089 ,  A61N2005/109 ,  A61N2005/1098

摘要： Methods for treating tumors by administering FLASH radiation and a therapeutic agent to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining therapeutic agents with FLASH radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with a therapeutic agent based on patient-specific biomarker signatures. Also provided are radiation treatment planning methods and systems incorporating FLASH radiation and therapeutic agents.

公开(公告)号：US11857808B2

公开(公告)日：2024-01-02

申请号：US16641917

申请日：2018-08-31

申请人： Mayo Foundation for Medical Education and Research

发明人： Douglas L. Packer ,  Samuel J. Asirvatham ,  Suraj Kapa

IPC分类号： G06T7/149 ,  A61N5/10 ,  G06T7/00 ,  G06T11/00

CPC分类号： A61N5/1049 ,  A61N5/1039 ,  G06T7/0012 ,  G06T7/149 ,  G06T11/005 ,  A61N2005/1058 ,  A61N2005/1087 ,  A61N2005/1098 ,  G06T2207/10081 ,  G06T2207/10088 ,  G06T2207/20116 ,  G06T2207/30048

摘要： Particle or hadron therapy is used on abnormal tissue using carbon atoms, protons, or helium atoms run through a linear accelerator and then directed at the target in the body. This can be used to treat, for example, atrial fibrillation, ventricular tachycardia, hypertension, seizures, gastrointestinal maladies, etc. Contouring and gating may be used to account for cardiac and respiratory motion, helping reduce collateral damage.

公开(公告)号：US20230414861A1

公开(公告)日：2023-12-28

申请号：US18449622

申请日：2023-08-14

申请人： BetaGlue Technologies S.p.A

发明人： Antonino Amato ,  Giovanni Paganelli

IPC分类号： A61M5/00 ,  A61M5/19 ,  A61M5/32 ,  A61M5/178 ,  A61K51/12 ,  A61J1/20 ,  A61N5/10

CPC分类号： A61M5/007 ,  A61M5/19 ,  A61M5/3294 ,  A61M5/1785 ,  A61K51/1251 ,  A61K51/1213 ,  A61N2005/1098 ,  A61N5/1007 ,  A61N5/1031 ,  A61N5/1027 ,  A61M2205/583 ,  A61M2210/1007 ,  A61J1/2096

摘要： Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

公开(公告)号：US11819548B2

公开(公告)日：2023-11-21

申请号：US17331674

申请日：2021-05-27

申请人： NANOBIOTIX S.A.

发明人： Elsa Borghi ,  Laurent Levy ,  Agnes Pottier

IPC分类号： B82Y5/00 ,  A61K9/14 ,  A61N5/10 ,  A61K41/00

CPC分类号： A61K41/0038 ,  A61K9/14 ,  B82Y5/00 ,  A61N2005/1087 ,  A61N2005/1089 ,  A61N2005/1098

摘要： The present application relates to activable inorganic nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cancerous cells, tissues or organs. It more particularly relates to nanoparticles which can generate a surprisingly efficient therapeutic effect, when concentrated inside the tumor and exposed to ionizing radiations. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.

公开(公告)号：US20230338521A1

公开(公告)日：2023-10-26

申请号：US17920860

申请日：2021-04-29

申请人： Roger M. PERLMUTTER ,  Maria Catherine PIETANZA ,  Merck Sharp & Dohme LLC

发明人： Roger M. Perlmutter ,  Maria Catherine Pietanza

IPC分类号： A61K39/395 ,  A61K31/502 ,  A61P35/00 ,  A61K33/243 ,  A61K31/519 ,  A61K31/7048 ,  A61K31/282 ,  A61K31/337 ,  A61N5/10

CPC分类号： A61K39/3955 ,  A61K31/502 ,  A61P35/00 ,  A61K33/243 ,  A61K31/519 ,  A61K31/7048 ,  A61K31/282 ,  A61K31/337 ,  A61N5/10 ,  A61N2005/1098

摘要： Provided herein are methods of treating cancer using a combination of (a) one or more programmed death 1 protein (PD-1) antagonists, (b) a radiotherapy, (c) one or more poly (ADP-ribose) polymerase (PARP) inhibitor, and optionally, (d) one or more chemotherapies. Also provided herein is a kit for pharmaceutical administration comprising: (a) a PD-1 antagonist; (b) a radiotherapy; (c) a PARP inhibitor; and (d) optionally, a chemotherapy. Further provided herein are uses of a combination for treating cancer in a human patient, wherein the combination comprises: (a) an effective amount of one or more PD-1 antagonists, (b) an effective amount of a radiotherapy, (c) an effective amount of a PARP inhibitor, and (d) optionally, one or more chemotherapies.

公开(公告)号：US11794033B2

公开(公告)日：2023-10-24

申请号：US17652784

申请日：2022-02-28

申请人： Westinghouse Electric Company LLC

发明人： John H. Nelson ,  Michael D. Heibel

IPC分类号： A61N5/10 ,  A61K41/00

CPC分类号： A61N5/10 ,  A61K41/009 ,  A61N2005/109 ,  A61N2005/1094 ,  A61N2005/1098

摘要： A process for treating highly localized carcinoma cells that provides precise positioning of a therapeutic source of highly ionizing but weakly penetrating radiation, which can be shaped so that it irradiates essentially only the volume of the tumor. The intensity and duration of the radiation produced by the source can be activated and deactivated by controlling the neutron flux generated by an array of electrically controlled neutron generators positioned outside the body being treated. The energy of the neutrons that interact with the source element can be adjusted to optimize the reaction rate of the ionized radiation production by utilizing neutron moderating material between the neutron generator array and the body. The source device may be left in place and reactivated as needed to ensure the tumor is eradicated without exposing the patient to any additional radiation between treatments. The source device may be removed once treatment is completed.

公开(公告)号：US20230284368A1

公开(公告)日：2023-09-07

申请号：US18177528

申请日：2023-03-02

申请人： TAE Technologies, Inc.

发明人： Alexander Dunaevsky ,  Gregory Luke Snitchler ,  Harrison Beam Eggers ,  Jedediah Styron ,  Charles Leon Lee

IPC分类号： H05H6/00 ,  A61N5/10

CPC分类号： H05H6/00 ,  A61N5/1043 ,  H05H2242/10 ,  A61N2005/109 ,  A61N2005/1098

摘要： Embodiments of systems, devices, and methods relate to exclusion of ion beam paths on the target surface to optimize neutron beam performance. A particle beam is directed along an axis so that the particle beam is incident on a target positioned on the particle beam axis. The target has a scannable surface extending over an area substantially orthogonal to the axis. The particle beam is scanned across the scannable surface of the target along a first path having a first flux. The particle beam, having a second flux, is scanned across the scannable surface of the target along a second path that is within an exclusion area of the target.